Physician profile
David A Janssen
NPI 1366420812
$54,246.31
in general payments reported to CMS, 2019-2025
27 companies · $921 in 2025
The $921 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $986 · 2020: $421 · 2021: $453 · 2022: $51K · 2023: $433 · 2024: $372 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709 · Travel and Lodging: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.34 |
| Travel and Lodging | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgical Innovation Associates, INC. | $50,000.00 | 2022 | |
| Sientra, INC. | $865.66 | 2019-2022 | |
| Mentor Worldwide LLC | $780.00 | 2019-2025 | Artoura Breast Tissue Expander, Mentor Memorygel Resterilizable Gel Sizer |
| Integra Lifesciences Corporation | $348.76 | 2022-2025 | Integra, Surgimend, Omnigraft |
| Becton, Dickinson and Company | $287.52 | 2025 | Phasix Mesh |
| Smith+Nephew, INC. | $234.74 | 2019-2025 | Pico 14, Renasys Go V2 Home, Pico 7 |
| Musculoskeletal Transplant Foundation INC. | $212.92 | 2019-2023 | |
| Motiva USA, LLC | $200.12 | 2025 | |
| Abbvie INC. | $178.47 | 2023-2025 | |
| Galderma Laboratories, L.P. | $165.65 | 2019-2021 | |
| Tepha INC | $157.19 | 2019 | |
| Allergan, INC. | $146.40 | 2019-2022 | |
| Davol INC. | $145.64 | 2022 | |
| Rti Surgical, INC | $82.39 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $75.58 | 2020-2023 | Exparel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $73.57 | 2021-2024 | |
| Tela Bio, INC. | $46.04 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Mindray Ds USA, INC. | $39.08 | 2023 | Te X, Te7 Max |
| Boston Scientific Corporation | $37.71 | 2022 | |
| Glaxosmithkline, LLC. | $33.36 | 2023 | Nucala |
| Coopersurgical, INC. | $30.54 | 2025 | Onetrac Lx |
| Avita Medical Americas, LLC | $24.18 | 2025 | Permeaderm, Recell, Cohealyx |
| Vertex Pharmaceuticals Incorporated | $21.36 | 2025 | |
| Biocompatibles, INC. | $16.96 | 2019 | |
| Misonix INC | $14.59 | 2019 | |
| Medtronic Vascular, INC. | $14.05 | 2019 | |
| W. L. Gore & Associates, INC. | $13.83 | 2025 | Gore Enform Preperitoneal Biomaterial |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Janssen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.